LEAP India and Molbio Diagnostics Get SEBI Approval to Launch IPOs


LEAP India and Molbio Diagnostics Get SEBI Approval to Launch IPOs
  • SEBI clears IPO plans of logistics firm LEAP India and diagnostics player Molbio Diagnostics.
  • LEAP India aims to raise up to Rs 2,400 crore, Molbio plans a mix of fresh issue and OFS.
  • Both companies plan capacity expansion and stronger market reach ahead of listing.

Logistics solutions provider LEAP India and Goa-based Molbio Diagnostics have received the green signal from the Securities and Exchange Board of India (SEBI) to launch their initial public offerings. The approvals mark a major step forward for both companies as they prepare to enter the public markets.

LEAP India had filed its DRHP earlier this year, proposing to raise up to Rs 2,400 crore. The IPO includes Rs 400 crore fresh issue and Rs 2,000 crore offer for sale. The bulk of the OFS will come from Vertical Holdings II Pte. Ltd., backed by global investor KKR, which plans to offload shares worth nearly Rs 1,999 crore. Another promoter entity, KIA EBT Scheme 3, will sell around Rs 13.8 crore worth of shares. Ahead of its listing plans, LEAP India converted into a public limited company in July 2025 and added independent directors to strengthen governance.

The company, which offers pallet, container and asset-pooling solutions to large FMCG, pharma and e-commerce players, has been scaling its fulfilment network to meet rising demand for efficient supply-chain infrastructure. In FY25, it posted Rs 466 crore in revenue, up 28% year-on-year, while maintaining a profit of Rs 37.5 crore.

Also Read: Swiggy Wins Shareholder Approval to Raise Rs 10,000 Crore via QIP

Molbio Diagnostics, best known for its Truenat point-of-care molecular testing platform, filed its DRHP in August 2025. Its IPO plan includes Rs 200 crore fresh issue and an OFS of up to 1.25 crore shares by existing investors including Exxora Trading LLP and individual shareholders. The company plans to use the proceeds to expand manufacturing and strengthen its R&D capabilities. Molbio reported Rs 1,020 crore in revenue and Rs 138.5 crore profit in FY25, underscoring strong demand for decentralised diagnostics across India and global markets.

SEBI has recently cleared IPO proposals from several tech and consumer-facing firms, signalling renewed momentum in India's capital markets.